Ibogaine clinical trials; Oklahoma Breakthrough Therapy Act; terms; requirements for drug developers; contractual terms; intellectual property rights; reports; intellectual property account; effective date.

Summary

The bill creates a framework for Oklahoma to partner with drug developers on ibogaine clinical trials, requiring developers to match state funding and conduct trials in‑state. It sets reporting requirements, creates an intellectual‑property account for any profits, and bars adverse licensing actions against Oklahoma‑licensed medical professionals. The goal is to accelerate FDA approval of ibogaine therapies while ensuring state benefits and patient access.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share